Oxford researchers use sovereign AI supercomputers to accelerate development of personalized cancer vaccines for individual patients.
|
Researchers at the University of Oxford are in the midst of a groundbreaking change in treating cancer with one of the UK's largest artificial intelligence systems to create personalized vaccines for each patient. The team has recently gained access to DAWN, one of the most powerful AI supercomputers in Britain, which is a significant milestone for them and the UK Cancer Vaccine AI & Supercomputing Project. The next stage of the development has received funding from the Medical Research Council and now provides a large consortium with over 2,500 people, including doctors, cancer scientists, AI specialists, robotic engineers, manufacturers, patients and partners.
CIARA is an innovative AI scientist platform that instructs cancer vaccine researchers on conducting experiments and analyzing complex tumor biology and helps guide researchers in creating personalized cancer vaccines. The use of CIARA fundamentally changes how scientists will treat cancer by moving away from one-size-fits-all approaches towards using precision medicine that takes into account the genetic makeup of an individual's tumor and the immune system of the patient. According to Dr. Lennard Lee, the Consultant Medical Oncologist and Project Director for this initiative, the introduction of this type of technology dramatically speeds up the time to develop a personalized cancer vaccine.
"It is now possible to move much faster from AI prediction towards real-world personalized drug development," Lee stated, highlighting how sovereign UK AI systems have unlocked capabilities previously unavailable to university researchers.
Researchers using the United Kingdom's computerized supercomputing systems (DAWN and ISAMBARD AI) are creating advanced computational models to analyze cancer and immune system data at a level of precision and speed that has never been possible before in traditional university-based computing environments. Through these systems, scientists have access to vastly increased computational capabilities, enabling them to determine the best vaccine targets for testing with greater speed and accuracy than they have ever had before. The MRC funding will support the next crucial steps of the project, which include acquiring manufacturing equipment needed to produce experimental mRNA cancer vaccines in order to determine if AI-directed vaccine targets will produce a strong enough immune response to prevent further progression of the disease.
The most pressing question from patients involved in the research program is whether AI technology will have any real benefit for cancer patients. The researchers will be able to answer this question by studying whether or not the vaccine targets selected using AI algorithms will produce a sufficient immune response to help control the patient's disease. The project enjoys broad support from multiple UK government and research institutions. Beyond the Medical Research Council, backing comes from UK Research and Innovation (UKRI), the Advanced Research and Invention Agency (ARIA), the Department for Science, Innovation and Technology, and Cancer Research UK.
Business Honor is of the view that the Medical Research Council's funding represents a strategic advancement in personalized cancer vaccine development and manufacturing capabilities.
.webp)
